Clinical trial
A Study of Abciximab and Reteplase When Administered Prior to Catherization…
NCT00046228 · Centocor, Inc., Industry · Completed
Key facts
| NCT number | NCT00046228 |
|---|---|
| Title | A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse) |
| Official title | A Muticenter, Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy and Safety of Reteplease and Abciximab Combination Therapy With Abciximab Alone Administered Early or Just Prior to Primary Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. |
| Lead sponsor | Centocor, Inc., Industry |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Myocardial Infarction |
| Intervention type | Drug |
| Interventions | abciximab placebo, reteplase placebo, abciximab, Abciximab, reteplase |
| Enrollment | 2,461 |
| Start date | Aug 1, 2002 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Sep 25, 2002 |
| Last update posted | Jul 31, 2014 |
| Countries | Argentina, Austria, Belgium, Bulgaria, Canada, Czechia, Denmark, France, Germany, Israel, Netherlands, Poland and 7 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: